-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GP-531 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GP-531 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GP-531 in Congestive Heart Failure (Heart Failure) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1821736 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1821736 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1821736 in Solid Tumor Drug Details: BI-1821736 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glenzocimab in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glenzocimab in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glenzocimab in Acute Ischemic Stroke Drug Details: Glenzocimab (Fab-9O12) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirfenidone in Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirfenidone in Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirfenidone in Pulmonary Fibrosis Drug Details: Pirfenidone (GP-101) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Misetionamide in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Misetionamide in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Misetionamide in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Melanoma Drug Details: RP-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Merkel Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Merkel Cell Carcinoma Drug Details: RP-1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Metastatic Melanoma Drug Details: RP-1 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Basal Cell Carcinoma...